BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, February 14, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 18, 2015
View Archived Issues
High-fat meal alters the pharmacokinetic profile of atorvastatin/metformin FDC
Read More
Galapagos introduces a new branimycin derivative DNA polymerase III inhibitor
Read More
Prolastin-C designated an orphan drug in U.S. for treating type 1 diabetes
Read More
Ruthigen and Pulmatrix to merge
Read More
GSK plans first-in-human study of GSK-2330811 for inflammatory and fibrotic diseases
Read More
Lakewood-Amedex and University of Jyvaskyla to test bisphosphocins for Borrelia burgdorferi
Read More
Galapagos regains rights to GLPG-1690 and announces end of alliance with Janssen
Read More
ADRA2A polymorphism associated with breast cancer severity
Read More
New genetic biomarkers associated with Hirschprung disease
Read More
Egalet earns milestone payment triggered by advancement of Shionogi's S-718632
Read More
Qiagen acquires CTC technology, enters companion diagnostic agreement with Tokai
Read More
Symbiomix's antibacterial drug candidate is safe and well tolerated
Read More
Actavis completes acquisition of Allergan
Read More
GlaxoSmithKline initiates phase III program of retosiban in preterm labor
Read More
Fujifilm reports novel ATM kinase inhibitors
Read More
Roche presents novel PAMs of muscarinic M1 receptor
Read More
Senju Pharmaceutical presents miRNA-203 inhibitor
Read More
GliaCure receives grant for phase Ib Alzheimer's trial
Read More
Neurotrope reports final results from phase IIa safety study of bryostatin 1 for Alzheimer's
Read More
Merck & Co. patents adenosine A2A receptor antagonists
Read More
Nektar Therapeutics discloses top-line results from phase III trial of NKTR-102 in breast cancer
Read More
Phase III study of Imbruvica combination meets primary endpoint
Read More
Celldex Therapeutics and Roche to evaluate the combination of varlilumab and MPDL-3280A
Read More
Iclusig now has U.S. and E.U. orphan drug status for gastrointestinal stromal tumors
Read More
Lundbeck initiates phase III study of clobazam in children with Dravet syndrome
Read More
